Literature DB >> 28533248

Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.

Atsuko Hachiya1,2, Karen A Kirby3, Yoko Ido4, Urara Shigemi4, Masakazu Matsuda4, Reiko Okazaki4, Junji Imamura4, Stefan G Sarafianos3,5, Yoshiyuki Yokomaku4, Yasumasa Iwatani4,6.   

Abstract

A novel HIV-1 integrase mutation pattern, L74F V75I, which conferred resistance to first-generation integrase strand transfer inhibitors (INSTIs), was identified in a clinical case with virological failure under a raltegravir-based regimen. Addition of L74F V75I to N155H or G140S Q148H increased resistance levels to the second-generation INSTIs dolutegravir (>385- and 100-fold, respectively) and cabotegravir (153- and 197-fold, respectively). These findings are important for the development of an accurate system for interpretation of INSTI resistance and the rational design of next-generation INSTIs.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  dolutegravir; drug resistance mechanisms; human immunodeficiency virus; integrase; integrase strand transfer inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28533248      PMCID： PMC5527620          DOI： 10.1128/AAC.00315-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Authors:  Tomokazu Yoshinaga; Masanori Kobayashi; Takahiro Seki; Shigeru Miki; Chiaki Wakasa-Morimoto; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Authors:  Olivia Goethals; Ann Vos; Marcia Van Ginderen; Peggy Geluykens; Veerle Smits; Dominique Schols; Kurt Hertogs; Reginald Clayton
Journal:  Virology       Date:  2010-04-24       Impact factor: 3.616

3.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

Authors:  Stephen Hare; Ann M Vos; Reginald F Clayton; Jan W Thuring; Maxwell D Cummings; Peter Cherepanov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-28       Impact factor: 11.205

4.  Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.

Authors:  Atsuko Hachiya; Hirotaka Ode; Masakazu Matsuda; Yumiko Kito; Urara Shigemi; Kazuhiro Matsuoka; Junji Imamura; Yoshiyuki Yokomaku; Yasumasa Iwatani; Wataru Sugiura
Journal:  Antiviral Res       Date:  2015-05-05       Impact factor: 5.970

5.  Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

Authors:  Atsuko Hachiya; Aaron B Reeve; Bruno Marchand; Eleftherios Michailidis; Yee Tsuey Ong; Karen A Kirby; Maxwell D Leslie; Shinichi Oka; Eiichi N Kodama; Lisa C Rohan; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

6.  Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome.

Authors:  Dario Oliveira Passos; Min Li; Renbin Yang; Stephanie V Rebensburg; Rodolfo Ghirlando; Youngmin Jeon; Nikoloz Shkriabai; Mamuka Kvaratskhelia; Robert Craigie; Dmitry Lyumkis
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

7.  Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.

Authors:  Signe Fransen; Soumi Gupta; Robert Danovich; Daria Hazuda; Michael Miller; Marc Witmer; Christos J Petropoulos; Wei Huang
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

Review 8.  Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.

Authors:  Luis Menéndez-Arias
Journal:  Antiviral Res       Date:  2013-02-08       Impact factor: 5.970

9.  Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Authors:  Olivia Goethals; Reginald Clayton; Marcia Van Ginderen; Inge Vereycken; Elisabeth Wagemans; Peggy Geluykens; Koen Dockx; Rudy Strijbos; Veerle Smits; Ann Vos; Geert Meersseman; Dirk Jochmans; Kurt Vermeire; Dominique Schols; Sabine Hallenberger; Kurt Hertogs
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

10.  The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness.

Authors:  Melissa Wares; Thibault Mesplède; Peter K Quashie; Nathan Osman; Yingshan Han; Mark A Wainberg
Journal:  Retrovirology       Date:  2014-01-17       Impact factor: 4.602
View more
  9 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.

Authors:  Said A Hassounah; Ahmad Alikhani; Maureen Oliveira; Simrat Bharaj; Ruxandra-Ilinca Ibanescu; Nathan Osman; Hong-Tao Xu; Bluma G Brenner; Thibault Mesplède; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

3.  High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

Authors:  Kate El Bouzidi; Steven A Kemp; Rawlings P Datir; Fati Murtala-Ibrahim; Ahmad Aliyu; Vivian Kwaghe; Dan Frampton; Sunando Roy; Judith Breuer; Caroline A Sabin; Obinna Ogbanufe; Man E Charurat; David Bonsall; Tanya Golubchik; Christophe Fraser; Patrick Dakum; Nicaise Ndembi; Ravindra K Gupta
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

4.  Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes.

Authors:  Leonard Rogers; Adetayo E Obasa; Graeme B Jacobs; Stefan G Sarafianos; Anders Sönnerborg; Ujjwal Neogi; Kamalendra Singh
Journal:  Front Microbiol       Date:  2018-08-02       Impact factor: 5.640

5.  A systematic review of the genetic mechanisms of dolutegravir resistance.

Authors:  Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

6.  Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.

Authors:  Sello Given Mikasi; Darren Isaacs; Rumbidzai Chitongo; George Mondide Ikomey; Graeme Brendon Jacobs; Ruben Cloete
Journal:  BMC Infect Dis       Date:  2021-04-23       Impact factor: 3.090

7.  HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria.

Authors:  Paul E Oluniyi; Fehintola V Ajogbasile; Shuntai Zhou; Iyanuoluwa Fred-Akintunwa; Christina S Polyak; Julie A Ake; Sodsai Tovanabutra; Michael Iroezindu; Morgane Rolland; Christian T Happi
Journal:  AIDS       Date:  2022-01-01       Impact factor: 4.632

8.  First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients.

Authors:  Farzane Ghasabi; Ava Hashempour; Nastaran Khodadad; Soudabeh Bemani; Parisa Keshani; Mohamad Javad Shekiba; Zahra Hasanshahi
Journal:  Biochem Biophys Rep       Date:  2022-03-29

9.  Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.

Authors:  Alina Kirichenko; Ilya Lapovok; Pavel Baryshev; David A M C van de Vijver; Jeroen J A van Kampen; Charles A B Boucher; Dimitrios Paraskevis; Dmitry Kireev
Journal:  Viruses       Date:  2020-07-31       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.